- Home
- ORGO vs AURA Comparison
ORGO vs AURA Comparison
Compare ORGO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGO | AURA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.6M | 333.4M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORGO | AURA |
|---|---|---|
| Price | $2.63 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.67 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 686.0K | 218.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | 9.33 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.84 | N/A |
| P/E Ratio | $17.67 | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $2.61 | $4.73 |
| 52 Week High | $7.08 | $7.73 |
Technical Indicators
Market Signals| Indicator | ORGO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 56.29 |
| Support Level | $2.61 | $5.81 |
| Resistance Level | $5.08 | $6.11 |
| Average True Range (ATR) | 0.22 | 0.39 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.66 | 65.69 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.